The Interaction Between Severe Acute Respiratory Distress Syndrome Viral Proteins and Monocytes

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00172263
First received: September 12, 2005
Last updated: December 6, 2012
Last verified: December 2012
  Purpose

Severe acute respiratory syndrome (SARS) is a new threat to public health since November, 2002. The SARS is highly contagious and is believed to be transmitted by person-to-person through droplet and direct contact. The patients present with fever, chills, cough, myalgia, dyspnea, and diarrhea. The symptoms aggravate in the second week and nearly 40% of the patients develop respiratory failure that requires assisted ventilation. The mortality rate is reported as 6.5%-7%.

After several months, the world scientists found the etiology to be a new coronavirus not belonging to the previous coronavirus group I, II and III. The new virus is called SARS associated coronavirus (SARS-CoV).

Although the high morbidity and mortality of SARS occurred in adults, there was rare mortality reported in the children. The report from Hong Kong pointed out that the symptoms of SARS in younger children were milder and the clinical course was not as aggressive as in adults. Therefore, the aim of the project is to design the experiment to see the differences of immunological responses to SARS-CoV protein in healthy younger children, teenagers, and adults. The investigators hope that the result could explain the reason for milder disease in younger children and the immunological pathogenesis of SARS.


Condition Intervention
Severe Acute Respiratory Syndrome
Procedure: blood sampling

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Enrollment: 0
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adults, children and cord blood
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00172263

Locations
China, Taiwan
Li-Chieh Wang, MD
Taipei, Taiwan, China, 100
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Li-Chieh Wang, MD National Taiwan University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00172263     History of Changes
Other Study ID Numbers: 9261701054
Study First Received: September 12, 2005
Last Updated: December 6, 2012
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
Immunology

Additional relevant MeSH terms:
Acute Lung Injury
Coronavirus Infections
Respiratory Distress Syndrome, Adult
Respiratory Distress Syndrome, Newborn
Severe Acute Respiratory Syndrome
Syndrome
Coronaviridae Infections
Disease
Infant, Newborn, Diseases
Infant, Premature, Diseases
Lung Diseases
Lung Injury
Nidovirales Infections
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Respiratory Tract Infections
RNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on October 20, 2014